these results were confirmed by the Center for Disease Control and Prevention's RT-PCR for pandemic (H1N1) 2009. This study was approved by the institutional review board of Rush University Medical Center.
There were 32 hospitalized patients, of which 16 were admitted to the intensive care unit (ICU). The most common diagnosis at hospital admission was pneumonia. Twenty-two (69%) of 32 patients received oseltamivir (44% of non-ICU vs 94% of ICU patients;
). The me-P p .002 dian duration of symptoms prior to hospitalization was 3 days (range, 1-7 days). The median duration from hospitalization to the administration of oseltamivir was 27.3 h (range, 3.1-222.5 h). Among patients treated with oseltamivir, the median duration from the time the drug was ordered to the time it was administered was 3.5 h (range, 1.2-17.7 h). Ten (46%) of 22 patients had a delay of у4 h from the time oseltamivir was ordered to the time of administration.
Empiric treatment for pandemic (H1N1) 2009 influenza is currently recommended for all hospitalized patients with suspected or proven influenza [1] . Recent observations suggest a mortality benefit of antiviral treatment for hospitalized patients with 2009 (H1N1) influenza and recommend that treatment be initiated as early as possible in hospitalized patients [2, 3] . We observed a significant delay (median, 27.3 h) in the initiation of oseltamivir treatment among hospitalized patients. This may be attributable to delays in diagnosis or turnaround of RT-PCR results (batched and performed daily at our institution). More significant is that despite the use of an electronic medication order system, almost one-half of patients treated with oseltamivir experienced a delay of у4 h before receiving the drug. This may be attributable to the fact that orders for oral antivirals are not viewed with the same urgency as intravenous antibiotics, which can be ordered "stat." The early administration of antibiotics has been demonstrated to have mortality benefit and is widely viewed as an important performance indicator [4] . The rapid initiation of antiviral therapy for influenza treatment should probably be viewed with similar importance [5] . The results of our study should encourage physicians, nurses, and pharmacists to examine closely all barriers to timely antiviral prescribing and administration. To the Editor-Carbapenems, such as imipenem and meropenem, are recommended as first-line therapy for severe infections caused by cephalosporin-resistant Enterobacteriaceae. The emergence of carbapenem-resistant enterobacteria is therefore worrisome from a public health point of view because (1) the antimicrobial treatment options are very limited and (2) they may represent therapeutic dead ends, as novel treatments against gramnegative bacteria are not expected in the near future.
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A 53-year-old male patient had a medical history of tuberculosis, fibromatosis, and chronic renal failure. Because of a peritoneal infection, he underwent abdominal surgery.
Strains of Hafnia alvei (H1), Enterobacter cloacae (E1), and Enterococcus faecalis were isolated from peroperative samples. The patient was treated with piperacillin-tazobactam after surgery, because H1, E1, and the E. faecalis isolates were susceptible. After 1 week, the patient became unstable and underwent surgery. Strains of H. alvei (H2) and E. cloacae (E2), both resistant to cephalosporins and piperacillin-tazobactam; an E. faecalis susceptible to ampicillin; and a methicillin-resistant coagulase-negative Staphylococcus were isolated, and the antibiotic therapy was changed to imipenem, vancomycin, gentamicin, and fluconazole. Twelve days later, a carbapenem-resistant H. alvei (H3) was isolated from a bronchoalveolar lavage sample and the therapy was changed to levofloxacin and gentamicin. Antibiotic resistance phenotypes and minimum inhibitory concentrations of carbapenems are presented in Table 1 . Unfortunately, the patient died 2 weeks later with multiple organ failure and acute respiratory distress syndrome.
H1, H2, and H3, initially identified as H. alvei with use of API 20E strips, were then identified as belonging to the very recent Hafnia paralvei sp nov (formerly known as H. alvei DNA group 2) [1] , by partial sequencing of RNA polymerase bsubunit (rpoB) and 16S ribosomal RNA genes. H1, H2, and H3 were indistinguish- able by pulsed field gel electrophoresis, as were E1 and E2. Repeated attempts to transfer carbapenem resistance from H3 to Escherichia coli by conjugation were unsuccessful, and no decrease in the minimum inhibitor concentrations of carbapenems was observed when plates supplemented with cloxacillin (for inhibition of cephalosporinase activity) or Etest containing EDTA (for inhibition of metallo-b-lactamases) were used. Analysis of outer-membrane proteins of H1, H2, and H3 by sodium dodecyl sulfate polyacrylamide gel electrophoresis revealed the lack of a major outer-membrane protein of 37 kDa in carbapenem-resistant isolate H3. This protein could correspond to OmpK36, known to play a role in permeability to carbapenems in Enterobacteriacae ( Figure 1 ) [2] . Among the medically important commensal Enterobacteriaceae [3] , carbapenem resistance has been so far reported in Citrobacter, Enterobacter, Escherichia, Klebsiella, Morganella, Proteus, and Providencia species [4] , but not in Hafnia species. Hafnia species are a cause of intestinal infections, especially in children, and of extraintestinal infections, in particular in adults with chronic underlying disease or previous antibiotic therapy [5] .
Ceftazidime resistance has been often reported since 1993 in Hafnia species [6] , but no resistance to the carbapenems has been observed. To our knowledge, this is the first report of carbapenem-resistant Hafnia, selected in a patient treated with imipenem. This indicates that the threat of carbapenem resistance is now present among all Enterobacteriaceae of medical importance, stressing more than ever the need for new antibiotics and new approaches against pan-resistant bacteria.
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